A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease

Figure 4 ANG3070 attenuates renal injury biomarkers and renal dysfunction. A-D: Compared to the WT cohort, at 14 wk of age, PCK [vehicle (Veh)] rats exhibited severe renal injury evidenced by increased urine - neutrophil gelatinase-associated lipocalin (NGAL) (A), kidney injury molecule-1 (KIM-1) (B), cystatin C (C) and interleukin-18 (IL-18) (D) (^bP < 0.01, vs WT). Treatment with ANG3070 was associated with a reduction in these urinary markers (A-D) of renal injury (^dP < 0.01, vs PCK + Veh); E-H: Renal dysfunction, evidenced by elevated proteinuria (E), albuminuria (F), blood urea nitrogen (BUN) (G) and serum creatinine (SCr) (H), was reduced with ANG3070 treatment (^bP < 0.01, vs WT; ^dP < 0.01, vs PCK + Veh).